Abstract

BackgroundIn a double-blind, breast cancer chemoprevention trial in young female subjects with a genetic predisposition (BRCA1\\2 mutation), the Hospital Pharmacy of the European Institute of Oncology developed a fenretinide formulation...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call